Johnson & Johnson (NYSE:JNJ) Posts Quarterly Earnings Results, Beats Expectations By $0.02 EPS

Johnson & Johnson (NYSE:JNJ) posted its quarterly earnings results on Tuesday, January 23rd. The company reported $1.74 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $1.72 by $0.02, Bloomberg Earnings reports. The firm had revenue of $20.20 billion for the quarter, compared to analyst estimates of $20.08 billion. Johnson & Johnson had a net margin of 1.70% and a return on equity of 27.80%. Johnson & Johnson’s revenue for the quarter was up 11.5% compared to the same quarter last year. During the same quarter last year, the firm posted $1.58 earnings per share. Johnson & Johnson updated its FY18 guidance to $8.00-8.20 EPS.

Shares of Johnson & Johnson (NYSE:JNJ) traded down $0.29 during midday trading on Wednesday, hitting $129.67. The company had a trading volume of 6,259,292 shares, compared to its average volume of 9,410,000. The company has a market cap of $348,360.00, a PE ratio of 332.49, a price-to-earnings-growth ratio of 2.34 and a beta of 0.74. The company has a current ratio of 1.32, a quick ratio of 1.02 and a debt-to-equity ratio of 0.36. Johnson & Johnson has a 1-year low of $115.32 and a 1-year high of $148.32.

The company also recently declared a quarterly dividend, which will be paid on Tuesday, March 13th. Investors of record on Tuesday, February 27th will be paid a $0.84 dividend. The ex-dividend date is Monday, February 26th. This represents a $3.36 annualized dividend and a dividend yield of 2.59%. Johnson & Johnson’s payout ratio is 861.54%.

A number of institutional investors have recently made changes to their positions in JNJ. Ladenburg Thalmann Financial Services Inc. lifted its holdings in shares of Johnson & Johnson by 1.1% during the fourth quarter. Ladenburg Thalmann Financial Services Inc. now owns 499,332 shares of the company’s stock worth $69,763,000 after buying an additional 5,337 shares during the last quarter. Flaharty Asset Management LLC lifted its holdings in shares of Johnson & Johnson by 23.9% during the fourth quarter. Flaharty Asset Management LLC now owns 3,232 shares of the company’s stock worth $459,000 after buying an additional 624 shares during the last quarter. G&S Capital LLC acquired a new position in shares of Johnson & Johnson during the fourth quarter worth approximately $759,000. TIAA CREF Investment Management LLC lifted its holdings in shares of Johnson & Johnson by 1.3% during the fourth quarter. TIAA CREF Investment Management LLC now owns 12,685,075 shares of the company’s stock worth $1,772,359,000 after buying an additional 167,079 shares during the last quarter. Finally, GHP Investment Advisors Inc. lifted its holdings in shares of Johnson & Johnson by 2.3% during the fourth quarter. GHP Investment Advisors Inc. now owns 35,561 shares of the company’s stock worth $4,969,000 after buying an additional 793 shares during the last quarter. 65.53% of the stock is owned by hedge funds and other institutional investors.

A number of analysts recently issued reports on the stock. BMO Capital Markets restated a “positive” rating and issued a $152.00 price target (up previously from $145.00) on shares of Johnson & Johnson in a research note on Wednesday, October 18th. Royal Bank of Canada lifted their price objective on shares of Johnson & Johnson from $144.00 to $147.00 and gave the stock an “outperform” rating in a report on Wednesday, October 18th. Leerink Swann reissued an “outperform” rating and set a $165.00 price target (up previously from $150.00) on shares of Johnson & Johnson in a report on Wednesday, October 18th. Wells Fargo & Co reissued an “outperform” rating and set a $155.00 price target (up previously from $149.00) on shares of Johnson & Johnson in a report on Wednesday, October 18th. Finally, Barclays lifted their price objective on shares of Johnson & Johnson from $140.00 to $148.00 and gave the company an “equal weight” rating in a research note on Wednesday, October 18th. Four equities research analysts have rated the stock with a sell rating, eight have assigned a hold rating, nine have given a buy rating and one has issued a strong buy rating to the company’s stock. The company presently has an average rating of “Hold” and a consensus price target of $146.16.

WARNING: “Johnson & Johnson (NYSE:JNJ) Posts Quarterly Earnings Results, Beats Expectations By $0.02 EPS” was first posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this piece on another domain, it was illegally stolen and reposted in violation of US & international copyright and trademark laws. The legal version of this piece can be read at https://www.dispatchtribunal.com/2018/02/14/johnson-johnson-jnj-posts-earnings-results-3.html.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.

Earnings History for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply